Skip to main content

Sotagliflozin

Healthy breakfast - symbolic image with model

07-21-2022 | Sotagliflozin | News

Sotagliflozin effects differ from empagliflozin only at breakfast

The only notable short-term differences in the effects of sotagliflozin and empagliflozin occur in glucose metabolism after breakfast, show findings from a randomized trial.

Heart failure

05-17-2021 | ACC 2021 | Conference coverage | News

Heart failure benefits of sotagliflozin consistent in preserved ejection fraction

The protective effect of sotagliflozin in people with type 2 diabetes and heart failure extends to those who have preserved ejection fraction, shows a prespecified pooled analysis of SOLOIST-WHF and SCORED.

05-17-2021 | ACC 2021 | Conference coverage | News

Sotagliflozin reduces overall hospital time for people with diabetes plus heart failure

Sotagliflozin treatment may reduce repeat hospitalizations and increase the amount of time people with type 2 diabetes and heart failure are alive and not in hospital, shows further analysis of SOLOIST-WHF.

Male orderly pushing male patient discharged from hospital in wheelchair

11-17-2020 | Sotagliflozin | News

SOLOIST-WHF: Sotagliflozin beneficial when started shortly after acute heart failure episode

Starting sotagliflozin in people with type 2 diabetes during or shortly after hospitalization for heart failure significantly reduces their risk for further cardiovascular events over the following months, show the results of the SOLOIST-WHF trial.

Kidneys

11-17-2020 | Sotagliflozin | Highlight | News

​​​​​​​Sotagliflozin SCORED cardiovascular risk reduction in people with type 2 diabetes, CKD

Add-on treatment with the SGLT1 and 2 inhibitor sotagliflozin may reduce cardiovascular risk among patients with type 2 diabetes and chronic kidney disease, suggest findings from the SCORED trial published in The New England Journal of Medicine.

04-12-2019 | Sotagliflozin | News

Meta-analysis demonstrates benefits of add-on sotagliflozin in type 1 diabetes

Adding the SGLT1/2 inhibitor sotagliflozin to insulin treatment improves glycemic and non-glycemic outcomes among people with type 1 diabetes, but at the cost of an increased risk for diabetic ketoacidosis, researchers report in The BMJ.

Checkboxes

02-12-2019 | SGLT2 inhibitors | Highlight | News

Recommendations issued for managing SGLT inhibitor-associated DKA risk in type 1 diabetes

Experts have developed consensus recommendations for minimizing diabetic ketoacidosis risk in patients with type 1 diabetes treated with SGLT inhibitors.

06-27-2018 | Sotagliflozin | ADA 2018 | News

SGLT2 inhibitor benefits in type 1 diabetes persist over longer term

The DEPICT-1 and inTandem1 investigators have released their 52-week findings, revealing persistent reductions in glycated hemoglobin with SGLT2 inhibition, but a slightly increased risk for diabetic ketoacidosis.